ArticleNature biomedical engineering2026
A deep learning and large language hybrid workflow for omics interpretation.
Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MAPA: A Semantic Network Framework for Functional Module Discovery and Interpretation in Multi-Omics Data.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Circadian clock gates diurnal glucose utilization.PLoS biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Profiling molecular panorama from massive omics data identifies regulatory networks in cells but requires mechanistic interpretation and experimental follow up. Here we combine deep learning and large language model reasoning to develop a hybrid workflow for omics interpretation, called LyMOI. LyMOI incorporates GPT-3.5 for biological knowledge reasoning and a large graph model with graph convolutional networks (GCNs). The large graph model integrates evolutionarily conserved protein interactions and uses hierarchical fine-tuning to predict context-specific molecular regulators from multi-omics data. GPT-3.5 then generates machine chain-of-thought (CoT) to mechanistically interpret their roles in biological systems. Focusing on autophagy, LyMOI mechanistically interprets 1.3 TB transcriptomic, proteomic and phosphoproteomic data and expands the knowledge of autophagy regulators. We also show that LyMOI highlights two human oncoproteins, CTSL and FAM98A, for enhancing autophagy upon treatment with disulfiram (DSF), an antitumour agent. Silencing these genes in vitro attenuates DSF-mediated autophagy and suppresses cancer cell proliferation. Strikingly, DSF treatment with Z-FY-CHO, a CTSL-specific inhibitor previously used for preventing SARS-CoV-2 infection, potently inhibits tumour growth in vivo.
Indexed as
Identifiers
41507521What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.